MYHEP AND MYDEKLA 12 WEEKS

MYHEP AND MYDEKLA 12 WEEKS

Drug profile
Myhep Mydekla tablets are anti-viral medication, containing two most predominant ingredients such as Sofosbuvir andDaclatasvir
Myhep Mydekla tablets are single dose therapy, it is a prescription medicine used by the patients only under the knowledge of medical practitioner who are well practiced
Mydekla tablet is not used alone, for better action it should be combined with Myhep tablet.
In some condition Myhep Mydekla is combined with ribavirin, an anti-viral medicine used in decompensated (Child Pugh B or C) cirrhosis

MYHEP AND MYDEKLA 12 WEEKS



Brand name: Myhep Mydekla
Active components: Myhep-Sofosbuvir, Mydekla-Daclatasvir
Strength of the components: 400mg & 60mg respectively
Mfg: Mylan pharmaceuticals
Package: 28 tablets in a container
Category: Anti-viral drug

Prescribing information for Myhep Mydekla
The main indication of Myhep Mydekla is;
This combination tablets are used to treat the chronic hepatitis C viral infection caused by genotype I or III
The major limitation occurred while using Myhep Mydekla tablets are reduction of constant virological response rate in hepatitis C genotype I or III infected patients.

Mechanism of Myhep Mydekla
The activity of Myhep Mydekla tablets are occurred by involving in some mechanism;
Myhep:
Myhep containing sofosbuvir has anti-hepaciviral activity, which is directly acting drug exhibits its action by prohibiting NS5B RNA reliant RNA polymerase enzyme; essential for hepatitis viral multiplication.
Sofosbuvir is metabolized to form uridine triphosphate, an essential active metabolite which exposes an anti-viral activity.
The infusion of this active metabolite into hepatitis viral RNA with the help of NS5B polymerase and causes viral chain discontinuation
Mydekla:
Mydekla containing Daclatasvir expels anti-viral activity by prohibiting NS5A protein which is needful in viral production and virion accumulation

Absorption
The peak plasma concentration of Mydekla tablets occurs within the range of 2 hours
The absolute bioavailability of Mydekla is 67%
The peak plasma concentration of Myhep tablets occurs within the range of 0.5 to 2 hours approximately.
The food will not creates any variation in absorption of Myhep Mydekla tablets, may be taken with or without food

Distribution
The volume of distribution in Mydekla tablet is 47L
The human plasma protein bound with Mydekla tablet is nearly 99%
The blood to plasma ratio of Myhep is relatively 0.7
The human plasma protein bound with Myhep occurs nearly 61 to 65%

Metabolism
Myhep is metabolized hepatically and formed as pharmacologically active metabolite uridine triphosphate, metabolism undergone with the help of cathepsin A or carboxylesterase 1
Mydekla metabolism occurred with the help of CYP3A4

Elimination
88% of Daclatasvir is excreted through feces 53% as an unchanged form, 6.6% excreted through urine.
The terminal half life period of Daclatasvir is occurred at 12 to 15 hours
Sofosbuvir metabolites are excreted through 80% in urine, 14% in feces & 2.5% in exhaled air
The terminal half life period of sofosbuvir is nearly 0.51 hours

How to take the Tablet Myhep Mydekla
Myhep Mydekla tablets are administered with or without food, in the condition of hepatitis C viral infection originated by genotype I or III
Myhep Mydekla is single dose regimen

Dosage regimens
Generally Daclatasvir is not used alone, it is combined with sofosbuvir
The recommended dosage of Myhep Mydekla is one tablet should be taken as a single dose
If sofosbuvir is discontinued, Daclatasvir also get stopped
Genotype I:
Patient suffered without cirrhosis or with compensated cirrhosis:
The recommended dosage of Myhep Mydekla is one tablet should be taken as a single dose with or without food
In decompensated cirrhosis patients:
Myhep Mydekla should be combined with ribavirin as a single dose
Genotype III:
Patient suffered without cirrhosis or with compensated cirrhosis:
The recommended dosage of Myhep Mydekla is one tablet should be taken as a single dose with or without food
In decompensated cirrhosis patients:
Myhep Mydekla should be combined with ribavirin as a single dose
The dosage of ribavirin;
On basis of body weight & hemoglobin level of patients, dose can be calculated.
Less than 75kg: 1000mg of ribavirin; in genotype I or III 600mg of ribavirin as an initial dose and followed as 1000mg/per
At least 75 kg: in decompensated cirrhosis 1200mg of ribavirin given as twice daily
The safety and efficacy of Mydekla has not been established <18 years
Myhep used in ≥12 years or weight of ≥35kg

Dosage adjustment in drug interaction;
If concurrent use with strong CYP3A inhibitors, the dosage of Mydekla is reduced to 30mg while co administration
Concurrent use with moderate CYP3A inducers, the dosage of Mydekla increased to 90mg
Concomitant use of Mydekla with CYP3A strong inducers should be avoided, it is contraindicated

Myhep Mydekla caused side effects
The most common side effects occurred during the therapy;
Headache
Fatigue
Nausea
Diarrhea
Elevation of lipase
Cardiac problems like symptomatic bradycardia
Insomnia
Pruritus
Myalgia
Pancytopenia
Asthenia
Rashes
Loss of appetite
Irritability
Neutropenia
Anemia
Chills
Influenza like symptoms
Pyrexia

Drug interaction
While combining Myhep Mydekla with strong CYP3A inducers causes loss of virological reaction rate of both products
Myhep Mydekla with HMG CoA reductase inhibitors, this combination leads to cause increasing the exposure of these drugs (statins)
CYP3A strong inducers like st Johns wort, rifampin, phenytoin or carbamazepine
If Myhep combines with P-gp or BCRP inhibitors leads to cause elevation of sofosbuvir plasma concentration
Myhep Mydekla tablets concomitant with amiodarone causes serious symptomatic bradycardia
Myhep Mydekla tablets concomitant with anti-convulsants, anti-mycobacterials or herbal products like st Johns wort causes decrease in effect of concentration of Myhep Mydekla

Food drug interaction
Myhep Mydekla with herbal product like st. Johns wort causes decreasing the therapeutic effect of Myhep Mydekla
No food drug interaction occurs
While using Myhep Mydekla tablets, caution should be taken
Diet should be discussed with consultant

Possible contraindications
Some contraindications occurs while using Myhep Mydekla tablets
In decompensated cirrhosis, combines with ribavirin contraindicated in pregnancy condition
Some anaphylactic reaction occurs if patients are contraindicated to the components present in Myhep Mydekla

Safety measures
Myhep Mydekla causes serious bradycardia while concurrent use with amiodarone, to prevent this condition some alternative medicine is given or discontinue the amiodarone if possible. Counsel the patients about the exposure of bradycardia during the treatment
Using Myhep Mydekla with ribavirin, should not be recommended in pregnancy condition because of producing fetal damage due to ribavirin
While taking Myhep Mydekla tablets, with CYP3A strong inducers causes loss of therapeutic response of Myhep Mydekla tablets. Avoid this concomitant to reduce the adverse effects

Pregnancy and lactation
Myhep Mydekla use in pregnancy, safe to use. The pregnancy category is B1
While combining with ribavirin, not recommended for pregnancy
Pregnancy category: X, causes fetal death
 Breast feeding should not be recommended

Storage and handling
The storage condition of Myhep Mydekla should be stored at room temperature below 30oC (86oF) & 20oC and 25oC (68oF and 77oF) respectively
Container should be keep away from heat, light and moisture

Missed dose
Both Myhep Mydekla tablets are single dose therapy, if patient fails to take the dose of these tablets, must consult the physician and take the dose within the time as per the instruction given by medical practitioner
Otherwise the missed dose should be skipped and follow the regular dosing schedule

Over dosage
The over dosage of Myhep Mydekla tablets are occurred due to missed dose , if once over dosage occurs the patients must be monitored frequently for endorsement of toxicity and provide safety measures
Hemodialysis is a procedure used to eliminate the component from body, sofosbuvir removes with separation coefficient of 54% whereas Daclatasvir is problematic because nearly 99% of drug bounded to human plasma protein

CONTACTS

Phone : +919940472902

USA Toll-Free Call : +18882264402

Email:millionhealthpharmaceuticals@gmail.com

WEBSITE: https://millionpharma.us/

Comments

Popular posts from this blog

LENALID 25MG

MYHEP-DVIR

HEPCINAT LP